Pfiz­er de­clares 'first-ever' PhI­II win for RSV vac­cine in in­fants — and it's steer­ing straight to FDA

In a first, Pfiz­er says it’s demon­strat­ed that it can pro­tect in­fants from res­pi­ra­to­ry syn­cy­tial virus by vac­ci­nat­ing their moth­ers dur­ing preg­nan­cy.

Pfiz­er is stop­ping …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER